| Identification | Back Directory | [Name]
2,2'-(4,4'-(4,4'-Methylenebis(2-chloro-4,1-phenylene))bis(azanediyl)bis(oxoMethylene)bis(azanediyl)bis(4,1-phenylene))bis(oxy)bis(2-Methylpropanoic acid) | [CAS]
245075-84-7 | [Synonyms]
LR-90
2,2'-{Methylenebis[(2-chloro-4,1-phenylene)carbamoylimino-4,1-phenyleneoxy]}bis(2-methylpropanoic acid)
2,2-[Methylenebis[(2-chloro-4,1-phenylene)iminocarbonylimino-4,1-phenyleneoxy]]bis[2-methylpropanoic acid]
Propanoic acid, 2,2'-[methylenebis[(2-chloro-4,1-phenylene)iminocarbonylimino-4,1-phenyleneoxy]]bis[2-methyl-
2,2'-((((((methylenebis(2-chloro-4,1-phenylene))bis(azanediyl))bis(carbonyl))bis(azanediyl))bis(4,1-phenylene))bis(oxy))bis(2-methylpropanoic acid)
2,2'-(4,4'-(4,4'-Methylenebis(2-chloro-4,1-phenylene))bis(azanediyl)bis(oxoMethylene)bis(azanediyl)bis(4,1-phenylene))bis(oxy)bis(2-Methylpropanoic acid) | [Molecular Formula]
C35H34Cl2N4O8 | [MDL Number]
MFCD26142431 | [MOL File]
245075-84-7.mol | [Molecular Weight]
709.57 |
| Chemical Properties | Back Directory | [Boiling point ]
726.0±60.0 °C(Predicted) | [density ]
1.448±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO : ≥ 100 mg/mL (140.93 mM);Water : < 0.1 mg/mL (insoluble) | [form ]
Solid | [pka]
3.01±0.10(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
LR-90 is an advanced glycation end product (AGE) inhibitor, inhibits inflammatory responses in human monocytes[1]. LR-90 is also used in the research of diabetic animal model[2]. | [Biological Activity]
Cell permeable: yes''Primary Target
=IF(SGM_MetricTransfer!C11=,,SGM_MetricTransfer!C11) | [in vivo]
LR-90 (50 mg/L, p.o. for 27 weeks) significantly reduces plasma lipids, modestly affects hyperglycaemia in ZDF rats[2].
LR-90 (50 mg/L) decreases renal AGE, AGER and lipid peroxidation[2]. | Animal Model: | Male ZDF rats (13 to 40 weeks)[2] | | Dosage: | 50 mg/L | | Administration: | P.O. for 27 weeks | | Result: | Significantly reduced plasma triacylglycerol and cholesterol by ～55% and ～30%, respectively. Modestly affected hyperglycaemia and blood pressure. Lowered the body weight. |
| [References]
[1] Figarola JL, et al. Anti-inflammatory effects of the advanced glycation end product inhibitor LR-90 in human monocytes. Diabetes. 2007 Mar;56(3):647-55. DOI:10.2337/db06-0936
[2] Figarola JL, et al. LR-90 prevents dyslipidaemia and diabetic nephropathy in the Zucker diabetic fatty rat. Diabetologia. 2008 May;51(5):882-91. DOI:10.1007/s00125-008-0935-x |
|
| Company Name: |
SPIRO PHARMA
|
| Tel: |
|
| Website: |
www.spiropharma.com.cn |
|